ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 1290
    Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study
  • Abstract Number: 395
    Systemic Lupus Erythematosus (SLE) with Inflammatory Myositis
  • Abstract Number: 2932
    Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology
  • Abstract Number: 2359
    Systemic Lupus Erythematous Outcome Concerns: Identifying Pain As the Major Discrepancy between Rheumatologists and Patients
  • Abstract Number: 1687
    Systemic Lupus Flares Based on BILAG and Sledai Rules Are Inconsistent, but May be Better Understood Using Visual Analogue Scales
  • Abstract Number: 1103
    Systemic Sclerosis Has a Distinct Serum Protein Profile That Correlates with Its Clinical Manifestations
  • Abstract Number: 1440
    Systemic Sclerosis in Pediatric Patients: An Epidemiological Study in a Large Insured Population in the US
  • Abstract Number: 2739
    Systemic Vasculitis: Incidence of Glucocorticoid Related Adverse Events
  • Abstract Number: 32
    T Cell-Intrinsic Nod2 Protects Against Th17-Mediated Autoimmune Arthritis in SKG Mice
  • Abstract Number: 147
    T Follicular Helper Cell Phenotype in RA Patients Receiving Rituximab
  • Abstract Number: 2946
    T Peripheral Helper Cells Are Expanded in the Circulation of Active SLE Patients and Correlate with CD21low B Cells
  • Abstract Number: 2808
    T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
  • Abstract Number: 2638
    Tacrolimus Use in Hispanic Patients with Refractory Lupus Nephritis
  • Abstract Number: 625
    Tapering of Biological Antirheumatic Drugs in Rheumatoid Arthritis Patients Is Achievable and Cost Effective in Daily Clinical Practice: DATA from the Brussels UCL RA Cohort
  • Abstract Number: 2574
    Tapering TNF Inhibitors in Axial Spondyloarthritis: Systematicanalysisoftheliteratureandmeta-Analysis
  • « Previous Page
  • 1
  • …
  • 172
  • 173
  • 174
  • 175
  • 176
  • …
  • 202
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology